EXECUTIVE MANAGEMENT AND COMPANY SECRETARY CHIEF EXECUTIVE OFFICER DR LEEARNE HINCH BSc BVMS MBA (appointed 7 November 2016) Dr Hinch is an experienced biotechnology executive and ASX-listed company CEO with extensive experience across corporate strategy, capital markets, global business development, technology commercialisation and product development spanning diagnostics, therapeutics, medical devices and animal health. Since joining INOVIQ, Dr Hinch has repositioned the Company around its proprietary exosome technologies, led multiple capital raisings, completed a transformational acquisition, expanded the Company’s intellectual property portfolio and built a diversified pipeline of diagnostics and therapeutics targeting major unmet needs in women’s health and oncology. Her experience includes establishing strategic collaborations, licensing agreements and commercial partnerships across the US, Europe and Asia-Pacific with leading academic institutions, biopharma, diagnostic developers and global industry partners. Dr Hinch brings hands-on leadership across corporate growth, investor relations, intellectual property management, clinical and regulatory strategy, commercial partnering and governance. Prior to INOVIQ, she founded life sciences consultancy Ingeneus Solutions and held executive and advisory roles with biotechnology companies including HealthLinx Ltd (ASX: HTX), OBJ Ltd (ASX: OBJ), Holista Colltech Ltd (ASX: HCT) and Chemeq Ltd (ASX: CMQ). She also held commercial and technical positions with multinational companies Virbac and Mars Petcare UK. Dr Hinch holds a Bachelor of Science, Bachelor of Veterinary Medicine and Surgery, and a Master of Business Administration (Distinction). FOUNDING SCIENTIST AND ADVISOR PROF GREGORY RICE PhD BSc (Hon) MHA Grad Dip Mgt (appointed 20 September 2021) Prof Rice is an internationally recognised academic and commercial scientist with over 30 years’ expertise and experience in oncology, perinatology, exosome-based research, clinical translational research, IVD development and commercialisation. He has held senior academic appointments, co-founded hospital-based clinical research centres in both oncology and perinatology, and co-founded and led diagnostic companies. He is an award-winning scientist with a strong international profile and clinical research networks. He has published more than 280 peerreviewed scientific publications and is a regular invited speaker at international conferences. He has held numerous academic leadership positions including at the University of Queensland (UQ), Baker Heart and Diabetes Institute, University of Melbourne, and Monash University. As Director of the UQ Centre for Clinical Diagnostics, he established the Centre, implemented an ISO17025 quality management system, secured NATA accreditation, and established an exosome research facility to evaluate the clinical utility of extracellular vesicles as liquid biopsies, IVDs and therapeutics. Additionally, he was a Founding Director and CSO of diagnostics company HealthLinx Ltd (ASX: HTX) and more recently CEO of Pregnostica SpA. His academic qualifications include a Doctor of Philosophy and Bachelor of Science (First Class Honours) from the University of Western Australia and a Graduate Diploma in Management and Master of Health Administration from RMIT University. CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY MR MARK EDWARDS BAcc CA (appointed 2 November 2022) Mr Edwards is a highly experienced and capable CFO and Company Secretary with expertise in financial leadership and management, corporate governance, investor relations and corporate transactions. Mr Edwards was previously CFO and Company Secretary at Medical Developments International Ltd (ASX: MVP) for 8 years, where he managed over $60 million in capital raisings, relocated the head office and manufacturing facility, established global infrastructure and operations and oversaw multiple new product launches. Previously he was Head of Finance and Company Secretary at Cogstate Ltd (ASX: CGS) and an Audit Senior Manager at Ernst & Young (EY) for 14 years, leading and managing professional staff in all aspects of audit, financial reporting, analysis and internal control across Manufacturing, Retail and Consumer Goods sectors, which included ASX listed clients. Directors’ Report continued 18 INOVIQ Limited
RkJQdWJsaXNoZXIy MjE2NDg3